Profund Advisors’s Maravai LifeSciences MRVI Stock Holding History

Profund Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,170	Closed	-$174K	–	1136
2022 Q4	$174K	Buy	12,170 +267	+2%	+$4.2K	0.01%	938
2022 Q3	$304K	Sell	11,903 -572	-5%	-$14.4K	0.02%	587
2022 Q2	$354K	Sell	12,475 -1,121	-8%	-$35.5K	0.02%	545
2022 Q1	$480K	Sell	13,596 -1,403	-9%	-$47K	0.02%	600
2021 Q4	$628K	Sell	14,999 -2,676	-15%	-$108K	0.02%	488
2021 Q3	$867K	Buy	17,675 +1,086	+7%	+$53K	0.03%	404
2021 Q2	$692K	Buy	+16,589	New	+$643K	0.02%	493

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Profund Advisors's MRVI Position: Q1 2023 in Review

Profund Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2023, closing a stake of 12,170 shares — an estimated $174K sold.

Profund Advisors first reported a position in MRVI in Q2 2021 and held it in 7 quarters. The position peaked at $867K in Q3 2021. 219 funds tracked by Wall St. Rank hold MRVI as of Q1 2023.

Profund Advisors reported no remaining Maravai LifeSciences position as of Q1 2023 after selling out during the quarter.
Profund Advisors sold 12,170 Maravai LifeSciences shares in Q1 2023, an estimated $174K.
Profund Advisors first reported a position in Maravai LifeSciences in Q2 2021 and held it in 7 quarters.
Profund Advisors's Maravai LifeSciences position peaked at $867K in Q3 2021.
219 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2023.

Based on Profund Advisors's 13F filing for Q1 2023, filed 12 May 2023.